RENE.L

ReNeuron Group Plc
ReNeuron Group plc - Directorate Change
17th April 2024, 10:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9914K
ReNeuron Group plc
17 April 2024
 

17 April 2024

 

ReNeuron Group plc

("ReNeuron", the "Group" or the "Company")

 

Resignation of Chief Financial Officer

 

ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that John Hawkins will be stepping down as Chief Financial Officer ("CFO") of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.

 

Iain Ross, Executive Chairman, said:

"The Board takes this opportunity to thank John for his valued contribution to the Group during his tenure and wish him every success for the future."

 

Enquiries:

 

Cork Gully LLP

+44 (0)20 7268 2150 or

Stephen Cork, Joint Administrator

reneuron@corkgully.com

Mark Smith, Joint Administrator


 


ReNeuron

www.reneuron.com/investors

Iain Ross, Executive Chairman

Via Walbrook PR





Allenby Capital Limited (Nominated Adviser and Broker)

+44 (0)20 3328 5656

James Reeve/George Payne/ Dan Dearden-Williams (Corporate Finance)


Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus / Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABGGDSLBBDGSR]]>
TwitterFacebookLinkedIn